{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:35Z","timestamp":1791397295405,"version":"4.3.3"},"reference-count":71,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0440","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:12:39Z","timestamp":1525237959000},"source":"Crossref","is-referenced-by-count":9,"title":["Fabry Disease"],"prefix":"10.3238","author":[{"given":"Bj\u00f6rn","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ertan","family":"Mayatepek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2009,6,26]]},"reference":[{"key":"10.3238\/arztebl.2009.0440_ref1","doi-asserted-by":"crossref","unstructured":"Spada M, Pagliardini S, Yasuda M et al.: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79: 31\u201340.","DOI":"10.1086\/504601"},{"key":"10.3238\/arztebl.2009.0440_ref2","doi-asserted-by":"crossref","unstructured":"Orteu CH, Jansen T, Lidove O et al.: Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007; 157: 331\u20137.","DOI":"10.1111\/j.1365-2133.2007.08002.x"},{"key":"10.3238\/arztebl.2009.0440_ref3","doi-asserted-by":"crossref","unstructured":"Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A: Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy\u2014a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23: 535\u201342.","DOI":"10.1097\/AJP.0b013e318074c986"},{"key":"10.3238\/arztebl.2009.0440_ref4","doi-asserted-by":"crossref","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S: Gastrointestinal symp-toms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007; 5: 1447\u201353.","DOI":"10.1016\/j.cgh.2007.08.012"},{"key":"10.3238\/arztebl.2009.0440_ref5","doi-asserted-by":"crossref","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S: Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 2007; 91: 210\u20134.","DOI":"10.1136\/bjo.2006.100602"},{"key":"10.3238\/arztebl.2009.0440_ref6","doi-asserted-by":"crossref","unstructured":"Hegemann S, Hajioff D, Conti G et al.: Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006; 36: 654\u201362.","DOI":"10.1111\/j.1365-2362.2006.01702.x"},{"key":"10.3238\/arztebl.2009.0440_ref7","doi-asserted-by":"crossref","unstructured":"Ries M, Kim HJ, Zalewski CK et al.: Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007; 130: 143\u201350.","DOI":"10.1093\/brain\/awl310"},{"key":"10.3238\/arztebl.2009.0440_ref8","doi-asserted-by":"crossref","unstructured":"Palla A, Hegemann S, Widmer U, Straumann D: Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 2007; 254: 1433\u201342.","DOI":"10.1007\/s00415-007-0575-y"},{"key":"10.3238\/arztebl.2009.0440_ref9","doi-asserted-by":"crossref","unstructured":"MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750\u201360.","DOI":"10.1136\/jmg.38.11.750"},{"key":"10.3238\/arztebl.2009.0440_ref10","doi-asserted-by":"crossref","unstructured":"Linhart A, Kampmann C, Zamorano JL et al.: Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28: 1228\u201335.","DOI":"10.1093\/eurheartj\/ehm153"},{"key":"10.3238\/arztebl.2009.0440_ref11","doi-asserted-by":"crossref","unstructured":"Monserrat L, Gimeno-Blanes JR, Marin F et al.: Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399\u2013403.","DOI":"10.1016\/j.jacc.2007.06.062"},{"key":"10.3238\/arztebl.2009.0440_ref12","doi-asserted-by":"crossref","unstructured":"Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M: Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 2008; 97: 463\u20139.","DOI":"10.1111\/j.1651-2227.2008.00700.x"},{"key":"10.3238\/arztebl.2009.0440_ref13","doi-asserted-by":"crossref","unstructured":"Hopkin RJ, Bissler J, Banikazemi M et al.: Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008; 64: 550\u20135.","DOI":"10.1203\/PDR.0b013e318183f132"},{"key":"10.3238\/arztebl.2009.0440_ref14","doi-asserted-by":"crossref","unstructured":"Tondel C, Bostad L, Hirth A, Svarstad E: Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 2008; 51: 767\u201376.","DOI":"10.1053\/j.ajkd.2007.12.032"},{"key":"10.3238\/arztebl.2009.0440_ref15","doi-asserted-by":"crossref","unstructured":"Branton MH, Schiffmann R, Sabnis SG et al.: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122\u201338.","DOI":"10.1097\/00005792-200203000-00003"},{"key":"10.3238\/arztebl.2009.0440_ref16","doi-asserted-by":"crossref","unstructured":"Buechner S, Moretti M, Burlina AP et al.: Central nervous system involvement in anderson-fabry diease: A clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008; 79: 1249\u201354.","DOI":"10.1136\/jnnp.2008.143693"},{"key":"10.3238\/arztebl.2009.0440_ref17","doi-asserted-by":"crossref","unstructured":"Rolfs A, Bottcher T, Zschiesche M et al.: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366: 1794\u20136.","DOI":"10.1016\/S0140-6736(05)67635-0"},{"key":"10.3238\/arztebl.2009.0440_ref18","doi-asserted-by":"crossref","unstructured":"Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A: Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003; 26: 787\u201394.","DOI":"10.1023\/B:BOLI.0000009948.86528.72"},{"key":"10.3238\/arztebl.2009.0440_ref19","doi-asserted-by":"crossref","unstructured":"Hughes DA, Elliott PM, Shah J et al.: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94: 153\u20138.","DOI":"10.1136\/hrt.2006.104026"},{"key":"10.3238\/arztebl.2009.0440_ref20","doi-asserted-by":"crossref","unstructured":"Ries M, Gupta S, Moore DF et al.: Pediatric Fabry disease. Pediatrics 2005; 115: e344\u201355.","DOI":"10.1542\/peds.2004-1678"},{"key":"10.3238\/arztebl.2009.0440_ref21","doi-asserted-by":"crossref","unstructured":"Eng CM, Guffon N, Wilcox WR et al.: Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9\u201316.","DOI":"10.1056\/NEJM200107053450102"},{"key":"10.3238\/arztebl.2009.0440_ref22","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Kopp JB, Austin HA et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743\u20139.","DOI":"10.1001\/jama.285.21.2743"},{"key":"10.3238\/arztebl.2009.0440_ref23","doi-asserted-by":"crossref","unstructured":"Moore DF, Scott LT, Gladwin MT et al.: Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104: 1506\u201312.","DOI":"10.1161\/hc3801.096352"},{"key":"10.3238\/arztebl.2009.0440_ref24","doi-asserted-by":"crossref","unstructured":"Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R: FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005; 42: 247\u201352.","DOI":"10.1136\/jmg.2004.025791"},{"key":"10.3238\/arztebl.2009.0440_ref25","unstructured":"Desnick RJ, Ioannou YA, Eng CM: alpha-galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, Valle D (eds.) The metabolic and molecular bases of inherited disease. New York: McGraw-Hill 2001: 3733\u2013810."},{"key":"10.3238\/arztebl.2009.0440_ref26","doi-asserted-by":"crossref","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249\u201354.","DOI":"10.1001\/jama.281.3.249"},{"key":"10.3238\/arztebl.2009.0440_ref27","doi-asserted-by":"crossref","unstructured":"Thadhani R, Wolf M, West ML et al.: Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249\u201355.","DOI":"10.1046\/j.1523-1755.2002.00097.x"},{"key":"10.3238\/arztebl.2009.0440_ref28","doi-asserted-by":"crossref","unstructured":"Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y: Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 2005; 9: 228\u201332.","DOI":"10.1007\/s10157-005-0369-4"},{"key":"10.3238\/arztebl.2009.0440_ref29","doi-asserted-by":"crossref","unstructured":"Kotanko P, Kramar R, Devrnja D et al.: Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15: 1323\u20139.","DOI":"10.1097\/01.ASN.0000124671.61963.1E"},{"key":"10.3238\/arztebl.2009.0440_ref30","doi-asserted-by":"crossref","unstructured":"Monserrat L, Gimeno-Blanes JR, Marin F et al.: Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399\u2013403.","DOI":"10.1016\/j.jacc.2007.06.062"},{"key":"10.3238\/arztebl.2009.0440_ref31","doi-asserted-by":"crossref","unstructured":"Mehta A, Ricci R, Widmer U et al.: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 2004; 34: 236\u201342.","DOI":"10.1111\/j.1365-2362.2004.01309.x"},{"key":"10.3238\/arztebl.2009.0440_ref32","doi-asserted-by":"crossref","unstructured":"O'Brien BD, Shnitka TK, McDougall R et al.: Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. Gastroenterology 1982; 82: 957\u201362.","DOI":"10.1016\/S0016-5085(82)80262-X"},{"key":"10.3238\/arztebl.2009.0440_ref33","doi-asserted-by":"crossref","unstructured":"Yamamoto K, Sobue G, Iwase S, Kumazawa K, Mitsuma T, Mano T: Possible mechanism of anhidrosis in a symptomatic female carrier of Fabry's disease: an assessment by skin sympathetic nerve activity and sympathetic skin response. Clin Auton Res 1996; 6: 107\u201310.","DOI":"10.1007\/BF02291231"},{"key":"10.3238\/arztebl.2009.0440_ref34","doi-asserted-by":"crossref","unstructured":"Lao LM, Kumakiri M, Mima H et al.: The ultrastructural characteris-tics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 1998; 18: 109\u201317.","DOI":"10.1016\/S0923-1811(98)00032-2"},{"key":"10.3238\/arztebl.2009.0440_ref35","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM et al.: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003; 28: 703\u201310.","DOI":"10.1002\/mus.10497"},{"key":"10.3238\/arztebl.2009.0440_ref36","doi-asserted-by":"crossref","unstructured":"Amann-Vesti BR, Gitzelmann G, Widmer U, Bosshard NU, Steinmann B, Koppensteiner R: Severe lymphatic microangiopathy in Fabry disease. Lymphat Res Biol 2003; 1: 185\u20139.","DOI":"10.1089\/153968503768330229"},{"key":"10.3238\/arztebl.2009.0440_ref37","doi-asserted-by":"crossref","unstructured":"Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ: Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002; 19: 575\u201386.","DOI":"10.1097\/00004691-200212000-00011"},{"key":"10.3238\/arztebl.2009.0440_ref38","doi-asserted-by":"crossref","unstructured":"Hoffmann B, Keshav S: Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007; 96: 84\u20136.","DOI":"10.1111\/j.1651-2227.2007.00216.x"},{"key":"10.3238\/arztebl.2009.0440_ref39","doi-asserted-by":"crossref","unstructured":"Cable WJ, Kolodny EH, Adams RD: Fabry disease: impaired autonomic function. Neurology 1982; 32: 498\u2013502.","DOI":"10.1212\/WNL.32.5.498"},{"key":"10.3238\/arztebl.2009.0440_ref40","doi-asserted-by":"crossref","unstructured":"Argoff CE, Barton NW, Brady RO, Ziessman HA: Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 1998; 19: 887\u201391.","DOI":"10.1097\/00006231-199809000-00009"},{"key":"10.3238\/arztebl.2009.0440_ref41","doi-asserted-by":"crossref","unstructured":"Ohkubo H: Several functional and fluorescein fundus angiographic findings in Fabry's disease. Ophthalmologica 1988; 196: 132\u20136.","DOI":"10.1159\/000309889"},{"key":"10.3238\/arztebl.2009.0440_ref42","doi-asserted-by":"crossref","unstructured":"Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A: Oph-thalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 2005; 33: 164\u20138.","DOI":"10.1111\/j.1442-9071.2005.00990.x"},{"key":"10.3238\/arztebl.2009.0440_ref43","doi-asserted-by":"crossref","unstructured":"Tsutsumi A, Uchida Y, Kanai T, Tsutsumi O, Satoh K, Sakamoto S: Corneal findings in a foetus with Fabry's disease. Acta Ophthalmol (Copenh) 1984; 62: 923\u201331.","DOI":"10.1111\/j.1755-3768.1984.tb08444.x"},{"key":"10.3238\/arztebl.2009.0440_ref44","doi-asserted-by":"crossref","unstructured":"Kono JO, Podskarbi T, Shin Y, Lanzl I: Oligosymptomatic cornea verticillata in a heterozygote for Fabry disease: a novel mutation in the alpha-galactosidase gene. Cornea 2003; 22: 175\u20137.","DOI":"10.1097\/00003226-200303000-00020"},{"key":"10.3238\/arztebl.2009.0440_ref45","doi-asserted-by":"crossref","unstructured":"Shen YD, Yang CM, Huang JS: Fabry disease manifesting as chronic uveitis\u2014treated with enzyme replacement therapy. Eye 2007; 21: 431\u20132.","DOI":"10.1038\/sj.eye.6702517"},{"key":"10.3238\/arztebl.2009.0440_ref46","doi-asserted-by":"crossref","unstructured":"Elstein D, Altarescu G, Zimran A: Uveitis and Fabry disease. Eye 2007; 21: 448\u20139.","DOI":"10.1038\/sj.eye.6702625"},{"key":"10.3238\/arztebl.2009.0440_ref47","doi-asserted-by":"crossref","unstructured":"Andersen MV, Dahl H, Fledelius H, Nielsen NV: Central retinal artery occlusion in a patient with Fabry's disease documented by scanning laser ophthalmoscopy. Acta Ophthalmol (Copenh) 1994; 72: 635\u20138.","DOI":"10.1111\/j.1755-3768.1994.tb07193.x"},{"key":"10.3238\/arztebl.2009.0440_ref48","doi-asserted-by":"crossref","unstructured":"Spaeth GL, Frost P: Fabry's disease. Its ocular manifestations. Arch Ophthalmol 1965; 74: 760\u20139.","DOI":"10.1001\/archopht.1965.00970040762005"},{"key":"10.3238\/arztebl.2009.0440_ref49","doi-asserted-by":"crossref","unstructured":"Germain DP, Avan P, Chassaing A, Bonfils P: Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3: 10.","DOI":"10.1186\/1471-2350-3-10"},{"key":"10.3238\/arztebl.2009.0440_ref50","doi-asserted-by":"crossref","unstructured":"Schachern PA, Shea DA, Paparella MM, Yoon TH: Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 1989; 98: 359\u201363.","DOI":"10.1177\/000348948909800509"},{"key":"10.3238\/arztebl.2009.0440_ref51","doi-asserted-by":"crossref","unstructured":"Shah JS, Hughes DA, Sachdev B et al.: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96: 842\u20136.","DOI":"10.1016\/j.amjcard.2005.05.033"},{"key":"10.3238\/arztebl.2009.0440_ref52","doi-asserted-by":"crossref","unstructured":"Chimenti C, Hamdani N, Boontje NM et al.: Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Am J Pathol 2008; 172: 1482\u201390.","DOI":"10.2353\/ajpath.2008.070576"},{"key":"10.3238\/arztebl.2009.0440_ref53","doi-asserted-by":"crossref","unstructured":"Weidemann F, Breunig F, Beer M et al.: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299\u2013301.","DOI":"10.1161\/01.CIR.0000091253.71282.04"},{"key":"10.3238\/arztebl.2009.0440_ref54","doi-asserted-by":"crossref","unstructured":"Frustaci A, Chimenti C: Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation 2007; 116: e350\u20131.","DOI":"10.1161\/CIRCULATIONAHA.107.723387"},{"key":"10.3238\/arztebl.2009.0440_ref55","doi-asserted-by":"crossref","unstructured":"Elliott PM, Kindler H, Shah JS et al.: Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357\u201360.","DOI":"10.1136\/hrt.2004.054015"},{"key":"10.3238\/arztebl.2009.0440_ref56","doi-asserted-by":"crossref","unstructured":"Whybra C, Kampmann C, Willers I et al.: Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715\u201324.","DOI":"10.1023\/A:1012993305223"},{"key":"10.3238\/arztebl.2009.0440_ref57","doi-asserted-by":"crossref","unstructured":"Ries M, Bettis KE, Choyke P et al.: Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004; 66: 978\u201382.","DOI":"10.1111\/j.1523-1755.2004.00846.x"},{"key":"10.3238\/arztebl.2009.0440_ref58","doi-asserted-by":"crossref","unstructured":"Glass RB, Astrin KH, Norton KI et al.: Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 2004; 28: 158\u201368.","DOI":"10.1097\/00004728-200403000-00002"},{"key":"10.3238\/arztebl.2009.0440_ref59","doi-asserted-by":"crossref","unstructured":"Crutchfield KE, Patronas NJ, Dambrosia JM et al.: Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50: 1746\u20139.","DOI":"10.1212\/WNL.50.6.1746"},{"key":"10.3238\/arztebl.2009.0440_ref60","doi-asserted-by":"crossref","unstructured":"Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R: White matter lesions in Fabry disease occur in \u201eprior\u201c selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62: 231\u201340.","DOI":"10.1016\/j.brainresbull.2003.09.021"},{"key":"10.3238\/arztebl.2009.0440_ref61","doi-asserted-by":"crossref","unstructured":"Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH: Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 2007; 30: 943\u201351.","DOI":"10.1007\/s10545-007-0708-6"},{"key":"10.3238\/arztebl.2009.0440_ref62","doi-asserted-by":"crossref","unstructured":"Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD: Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 2002; 11: 127\u201333.","DOI":"10.1023\/A:1015009210639"},{"key":"10.3238\/arztebl.2009.0440_ref63","doi-asserted-by":"crossref","unstructured":"Desnick RJ: Prenatal diagnosis of Fabry disease. Prenat Diagn 2007; 27: 693\u20134.","DOI":"10.1002\/pd.1767"},{"key":"10.3238\/arztebl.2009.0440_ref64","doi-asserted-by":"crossref","unstructured":"Lee K, Jin X, Zhang K et al.: A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13: 305\u201313.","DOI":"10.1093\/glycob\/cwg034"},{"key":"10.3238\/arztebl.2009.0440_ref65","doi-asserted-by":"crossref","unstructured":"Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M: Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2008; 29: 353\u201361.","DOI":"10.1159\/000168482"},{"key":"10.3238\/arztebl.2009.0440_ref66","unstructured":"Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G: Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006; 66: 77\u201384."},{"key":"10.3238\/arztebl.2009.0440_ref67","doi-asserted-by":"crossref","unstructured":"Kovacevic-Preradovic T, Zuber M et al.: Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 2008; 9: 729\u201335.","DOI":"10.1093\/ejechocard\/jen129"},{"key":"10.3238\/arztebl.2009.0440_ref68","doi-asserted-by":"crossref","unstructured":"Weidemann F, Breunig F, Beer M et al.: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108: 1299\u2013301.","DOI":"10.1161\/01.CIR.0000091253.71282.04"},{"key":"10.3238\/arztebl.2009.0440_ref69","doi-asserted-by":"crossref","unstructured":"Hilz MJ, Brys M, Marthol H, Stemper B, D\u00fctsch M: Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004 ; 62: 1066\u201372.","DOI":"10.1212\/01.WNL.0000118207.84514.40"},{"key":"10.3238\/arztebl.2009.0440_ref70","doi-asserted-by":"crossref","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM et al.: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003; 28: 703\u201310.","DOI":"10.1002\/mus.10497"},{"key":"10.3238\/arztebl.2009.0440_ref71","doi-asserted-by":"crossref","unstructured":"Moore DF, Altarescu G, Ling GS et al.: Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33: 525\u201331.","DOI":"10.1161\/hs0202.102601"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T04:37:28Z","timestamp":1638851848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,26]]},"references-count":71,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0440","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1155\/2013\/207573","asserted-by":"object"},{"id-type":"doi","id":"10.1155\/2015\/504784","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,26]]}}}